Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders

NCT01740869 Phase 3 COMPLETED

The purpose of this study is to determine whether the plasticity of autologous intrathecal hematopoietic cells would improve the neurologic and the social skills of pediatric patients with autism spectrum disorders.

Details

Lead sponsor	Hospital Universitario Dr. Jose E. Gonzalez
Phase	Phase 3
Status	COMPLETED
Enrolment	30
Start date	2012-11
Completion	2017-10

Conditions

• Autism
• Autism Spectrum

Interventions

• Autologous Intrathecal Hematopoietic Stem Cells
• Observation with IDEA and CARS Scales

Primary outcomes

• Change in Childhood Autism Rating Scale (CARS) score — Baseline, 30 days, and 180 days
  CARS scale will be used to evaluate changes in autistic behavior and social interaction after treatment. Participants will be assessed at baseline, 30 days, and 180 days to measure improvement following the intrathecal infusion of autologous CD34+ hematopoietic stem cells.

Countries

Mexico